India's pharma sector braces for impact of proposed Trump tariffs on generic drugs
Get the Geopolitics newsletter
Daily geopolitics — wars, elections, sanctions, the diplomatic moves that move markets. Free.
- India supplies nearly half of all generic medicines consumed in the US, with the US accounting for US$9.7 billion (38%) of India's US$25.8 billion in pharmaceutical exports in 2025
- Trump's proposed plan imposes a two-year tariff-free window, then 100% tariffs from August 2028 and 200% from August 2029, framed as a penalty to companies that don't build US manufacturing
- Indian drugmakers with existing US facilities are best positioned to weather the tariffs, but must decide which products to shift to American plants, per Vector Consulting Group's Chandrachur Datta
- Analysts including Joseph Carrello of the Melbourne School of Population and Global Health say the tariff is effectively a tax on US consumers, reducing competition and pushing prices higher
- Manufacturers face uncertainty over whether tariffs apply only to finished medicines or also to imported active pharmaceutical ingredients, where China dominates production including amoxicillin
- Indian pharmaceutical stocks have fallen since the announcement, with investors watching the upcoming quarterly earnings season for company-by-company response strategies
Why it matters: Indian pharma exporters face a 200% tariff wall by August 2029 on US$9.7 billion in annual sales, and the attempted workaround — reshoring to US factories — may not pencil out given generics' thin margins, meaning American patients who fill more than 90% of prescriptions with generics will likely absorb the cost.
